Rayner Announces New Leadership Team to Drive the Company Through a Major Transformation.

Rayner Intraocular Lenses Limited (‘Rayner’), the pioneering manufacturer of intraocular lenses, today announces several changes to the senior management team.  The appointments reflect renewed focus on Rayner’s surgical business following the divestment earlier last year of Rayner’s retail optometry business. The move will be complemented by a move later this year to The Ridley Innovation Centre, a brand new state-of-the art global headquarters and production facility in Worthing, West Sussex, UK. This major investment will enable Rayner to double its manufacturing capacity and support the company’s ambitious business expansion.

Rayner’s leadership team now includes the following:

Tim Clover – Joint CEO and New Projects Director. Tim joined the Rayner Group Board in May 2014 and has an accomplished career in the medical devices sector. He was a founder and European VP of Advanced Medical Optics which was spun out of Allergan Inc, listed on the NYSE and subsequently acquired by Abbott Inc.  More recently, Tim was CEO of Moonray Healthcare, a private equity fund within Fidelity Worldwide Investments in which Optegra, the specialist eye hospital business, was a landmark investment. Tim has an intimate understanding of the ophthalmology market and is passionate about innovation – an integral part of the Rayner brand. Tim’s role is part-time and focussed on external opportunities for the company.

Darren Millington - Joint CEO and CFO. Darren joined the Rayner Group Board in August 2014 with 8 years’ experience as CFO in both public and private companies.  His previous position was CFO at Gama Aviation, an aviation and engineering company with operations around the world and revenues over $200m. Darren brings to Rayner a wealth of experience in helping companies grow through investment and acquisition.

Andrew Webb – Global Vice-President, Commercial.   Andrew joined Rayner in January 2015, bringing with him over twenty seven years’ experience in the ophthalmology industry.  He has held various senior management positions whilst at his previous company, Bausch + Lomb, most recently as Vice President Commercial EMEA. He has an excellent track record for delivering commercial execution and rapid growth whilst fostering high quality, patient centric market-development. Andrew brings a customer-focused approach to the role and will develop and further enhance Rayner’s well-established links with the ophthalmic surgeon community.

“Over the last number of years, these leaders have made significant contributions to the success of their respective organisations and I am very pleased that they have agreed to join me in leading Rayner into an exciting new future. We have carefully structured the team to ensure that we are in the best position to enable a period of rapid growth for the company, aspiring to build a leadership position in the global intraocular lens market whilst continuing to deliver long- term stakeholder value. The Rayner Board warmly welcomes our new leadership.” commented Niels de Coninck-Smith – Chairman of Rayner Surgical Group.

-ENDS-

Rayner Intraocular Lenses Limited (‘Rayner’), the pioneering intraocular lens (‘IOL’) manufacturer has over 65 years of dedication to improving vision and the restoration of sight worldwide. Today, Rayner’s mission remains that of delivering innovative and clinically superior ophthalmic products that consistently respond to the expectations of our global customers and reward the profound trust placed in the Company to improve sight and quality of life.

Headquartered in Hove, East Sussex, United Kingdom, Rayner markets its IOL portfolio and related products worldwide through a network of distributors in over 70 countries and a direct sales team in the United Kingdom, USA, Germany and Austria.

For questions please contact Rayner at iol_enquiries@rayner.com